Topics

Latest "Therapure Biomanufacturing" News Stories

02:22 EST 22nd February 2020 | BioPortfolio

Here are the most relevant search results for "Therapure Biomanufacturing" found in our extensive news archives from over 250 global news sources.

More Information about Therapure Biomanufacturing on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Therapure Biomanufacturing for you to read. Along with our medical data and news we also list Therapure Biomanufacturing Clinical Trials, which are updated daily. BioPortfolio also has a large database of Therapure Biomanufacturing Companies for you to search.

Showing "Therapure Biomanufacturing" News Articles 1–25 of 116

Thursday 20th February 2020

Living systems are being reprogrammed to boost biomanufacturing output, manage #microbiome interactions, produce smart materials, and advance #PrecisionMedicine -- http://ow.ly/Aru150yrMzD pic.twitter.com/Eew48q7Rn6

Living systems are being reprogrammed to boost biomanufacturing output, manage #microbiome interactions, produce smart materials, and advance #PrecisionMedicine -- http://ow.ly/Aru150yrMzD  pic.twitter.com/Eew48q7Rn6


LumaCyte Expands into Europe Tackling Expansive Vaccine and Cell and Gene Therapy Markets

LumaCyte, an advanced bioanalytical instrumentation company specializing in vaccine and cell and gene therapy bioprocess, production, and R&D analytical capabilities, announces its expansion into Europe with the establishment of LumaCyte, B.V. in The Netherlands. LumaCyte has experienced a rapid increase in global demand for Radiance®, it’s label-free single cell analysis instrument, with ...

Wednesday 19th February 2020

Univercells expands its offering to meet ‘fast-growing’ gene therapy demand

Funding from Gamma supports the development of Univercellsâ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.


Tuesday 18th February 2020

Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina

- Audentes plans to invest over $100 million and create over 200 new jobs in Lee County Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot, state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. The initial phase of the capital in...

Univercells Secures up to €50M Investment from KKR Platform to Speed Delivery of Manufacturing Technologies

Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced biologic therapies ...

KKR Forms Life Sciences Tools Platform Gamma Biosciences

New Platform to Support Innovation in Bioprocessing for Advanced Biologic Therapies KKR, a leading global investment firm, today announced the formation of a new platform, Gamma Biosciences (“Gamma” or “the Company”), which will operate a portfolio of companies focused on next-generation bioprocessing technologies for the production of advanced biologic therapies. KKR and co-investors ha...

Wednesday 12th February 2020

WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak

SHANGHAI, Feb. 12, 2020 /PRNewswire/ -- WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to mitigate any potential risk. All three operating sites in China, namely Wuxi, Shanghai and Suzhou, will resume operations today after the Chinese New Year break. Overall, approximately 6% of our staff have ...

Tuesday 11th February 2020

Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that develops n...

Monday 10th February 2020

Maryland Tech Council Expands to Frederick to Create Larger Footprint in State of Maryland

- Forming Workforce Coalition in Frederick to address issues tied to attracting and retaining human capital - Coordinating with Universities at Shady Grove to establish its Montgomery County offices - Launched “We are Here” Campaign to Emphasize Reach and Impact Throughout the State The Maryland Tech Council (MTC) announced today it has expanded its offices to Frederick to broaden its re...

Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has successfully produced its trimeric Spike-protein (“S-Trimer”) subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system. In addition, Clover scientists have used the newly obtained S-Trimer and successfully...

Friday 7th February 2020

Living systems are being reprogrammed to boost biomanufacturing output, manage microbiome interactions, produce smart materials, and advance precision medicine, Michael Eisenstein reports: http://ow.ly/naXB50yfq4Y pic.twitter.com/oKbX0wFVCE

Living systems are being reprogrammed to boost biomanufacturing output, manage microbiome interactions, produce smart materials, and advance precision medicine, Michael Eisenstein reports: http://ow.ly/naXB50yfq4Y  pic.twitter.com/oKbX0wFVCE

Saturday 1st February 2020

Keeping Biomanufacturing Flexible -- http://ow.ly/YVmw50y81rH pic.twitter.com/reTPoi29eB

Keeping Biomanufacturing Flexible -- http://ow.ly/YVmw50y81rH  pic.twitter.com/reTPoi29eB

Wednesday 29th January 2020

In #biomanufacturing, being ready to adapt as needed could determine ongoing success, @TechTyper reports -- http://ow.ly/YVmw50y81rH pic.twitter.com/02J0CvN5AD

In #biomanufacturing, being ready to adapt as needed could determine ongoing success, @TechTyper reports -- http://ow.ly/YVmw50y81rH  pic.twitter.com/02J0CvN5AD

Keeping Biomanufacturing Flexible -- http://ow.ly/YVmw50y81rH pic.twitter.com/1XfsF6uxsz

Keeping Biomanufacturing Flexible -- http://ow.ly/YVmw50y81rH  pic.twitter.com/1XfsF6uxsz

Tuesday 28th January 2020

Keeping Biomanufacturing Flexible

When a biomanufacturer takes on a new client, the eventual outcome cannot be known. One project could involve clinical trial material for a treatment that never reaches the market and another could turn into a Humira-like blockbuster. To stay alive and profitable, a biomanufacturer must be ready to change course when needed—from turning to an […] The post Keeping Biomanufacturing Flexible ...

Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that it has initiated development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus that is believed to have originated from Wuhan, China. Since this outbreak was first reported in late-2019, the 2019-nCov viru...

Friday 24th January 2020

VIDEO: Boyd Releases “Global Biomanufacturing Costs” Report

John Boyd discusses details from his firm's new biomanufacturing site selection costs report.

Tuesday 21st January 2020

InnovationXLab Biomanufacturing Summit aims to push scientific frontiers and boost bioeconomy

(DOE/Lawrence Berkeley National Laboratory) Next week, Berkeley Lab is hosting the InnovationXLab Biomanufacturing Summit: An exclusive event aimed at bridging the gap between research and commercialization and paving the way toward a stronger bioeconomy.

3i Establishes a Single-Use Bioprocessing Platform

Major move that is designed to serve the global biopharmaceutical industry by the acquisitions of Cellon, Silicone Altimex, and TBL Performance Plastics along with a variety of biomanufacturing-focused products. The post 3i Establishes a Single-Use Bioprocessing Platform appeared first on GEN - Genetic Engineering and Biotechnology News.

Modality Solutions Announces 2019 Year-End Milestones Including ISO 9001:2015, Inc. 5000, Entrepreneur 360™ and More

Houston-based Modality Solutions, a biopharmaceutical cold chain engineering firm, reports 2019 its strongest year ever, driven by national awards, ISO 9001:2015 certification, Forbes Tech Council membership, and more. HOUSTON (PRWEB) January 21, 2020 Modality Solutions specializes in integrating cold chain operations, developing transport validation strategies, supporting global regulatory appli...

Thursday 16th January 2020

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company ...

Tuesday 14th January 2020

AbSci Closes $15.4 M in Series D Funding to Accelerate Growth and Scale Disruptive Protein PrintingTM Technology, Announces Exclusive Co-Marketing Partnership with KBI Biopharma

VANCOUVER, Wash., Jan. 13, 2020 /PRNewswire/ — AbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences. Existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and […] T...

Monday 13th January 2020

Just - Evotec Biologics Enters into Multi-Year Collaboration With MSD Around Facility of the Future

MSD TO GAIN ACCESS TO MANUFACTURING KNOW-HOW WITHIN JUST - EVOTEC BIOLOGICS' J.POD(R) FACILITY ("FACILITY OF THE FUTURE") MULTI-YEAR COLLABORATION IN FORM OF CAPACITY RESERVES FOR PRODUCTION OF MSD BIOLOGICS HAMBURG, GERMANY / ACCESSWIRE / January 14, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its wholly-owned Seattle...

Just - Evotec Biologics Initiates Construction of First J.POD(R) Facility in North America

THE J.POD(R) TECHNOLOGY EXPANDS EVOTEC'S CAPABILITIES INTO FLEXIBLE COMMERCIAL BIOLOGICS MANUFACTURING CONFIRMS EVOTEC'S ROLE AS LEADING EXTERNAL INNOVATOR FOR THE INTEGRATED OUTSOURCING OF DRUG DISCOVERY AND DEVELOPMENT ADDS CLINICAL DEVELOPMENT AND COMMERCIAL SUPPLY FOR BOTH NICHE AND LARGER QUANTITIES OF DRUG SUBSTANCE EVOTEC'S PARTNERS WILL BENEFIT FROM FLEXIBLE, HIGH QUALITY...

Saturday 11th January 2020

Engaging the @US_FDA on #Innovation in Biomanufacturing: http://ow.ly/qf1D50xQb4j pic.twitter.com/4lVlTpVh00

Engaging the @US_FDA on #Innovation in Biomanufacturing: http://ow.ly/qf1D50xQb4j  pic.twitter.com/4lVlTpVh00


Quick Search

News Quicklinks